CyGenica raised the money in a seed fund investment round led by global venture capital investor SOSV. CyGenica will use the funding to accelerate the validation of its technology which is designed to enable safe, targeted and affordable intercellular drug delivery.
CyGenica’s technology aims to address the problem of delivering large-molecule therapeutics into living cells without damaging them or triggering an adverse immune response.
CyGenica is now seeking a key partner of biopharmaceutical companies in the advancement of cutting-edge therapeutics for cancer and rare diseases to improve patient’s health and quality of life.
